AR and prostate carcinoma: revealed that ectopic JAK‐STAT activation in prostate cancer can drive resistance to AR‐targeted therapies by promoting stem‐like subclones with multilineage transcriptional programs, rather than restricting transition to NE‐like lineage [165].